连发Cell子刊：杨莉莉团队开发现货型CAR-NKT细胞疗法，治疗多种实体瘤

Core Viewpoint - The article discusses the advancements in Allo CAR-NKT cell therapy as a promising treatment for renal and ovarian cancers, highlighting its potential to overcome limitations of traditional CAR-T therapies [2][3]. Group 1: Allo CAR-NKT Cells in Renal Cancer - Allo CAR-NKT cells, targeting CD70, show strong cytotoxicity against both primary and metastatic renal cell carcinoma (RCC) [8]. - The study indicates that these cells can effectively target the immunosuppressive tumor microenvironment (TME) and eliminate CD70+ host alloreactive T cells, enhancing treatment durability [10]. - The research supports the potential of Allo CAR-NKT cells as a next-generation off-the-shelf immunotherapy for metastatic RCC [10]. Group 2: Allo CAR-NKT Cells in Ovarian Cancer - Allo CAR-NKT cells demonstrate unique efficacy and safety advantages in treating ovarian cancer, addressing challenges such as tumor heterogeneity and immune evasion [15][16]. - The engineered Allo15 M CAR-NKT cells exhibit superior anti-ovarian cancer effects compared to traditional CAR-T cells, with mechanisms targeting both tumor cells and the TME [15]. - These cells have a lower incidence of cytokine release syndrome and do not induce graft-versus-host disease (GvHD), making them a safer option for patients [15][16].